<p>Close up of a middle aged woman dressed in a blazer, sitting down while looking at another person in the foreground.</p>

Welcome to Mendus’ Investor Relations page. Mendus is listed on NASDAQ Stockholm under the ticker symbol IMMU. You will find all relevant information on the Mendus share in our Investors section.

Letter from the CEO

The positive Phase 2 data we presented at the American Society for Hematology conference last December for our lead program vididencel (DCP-001) in acute myeloid leukemia (AML) provide the basis for broader positioning and, eventually, the path to market registration of vididencel as a new maintenance treatment in AML. We also reported the first positive clinical safety data with vididencel in ovarian cancer and completed the preparations for a next clinical trial with our intratumoral primer ilixadencel. We are very happy with the progress we have made on all fronts in 2022 and the continued commitment of our entire team to develop impactful new cancer therapies. For 2023, we have taken necessary steps to focus on our most value-generating projects.

To read the full letter from the CEO, please click here.

Latest Company Presentation

View the latest company presentation


ASH 2022 Webcast

Watch the replay


Mendus KOL Event – November 2022

Watch the replay


Latest press releases

Upcoming Events


<p>Image of old buildings by a dock with boats laying in the water in the foreground.</p>

Head Office

Västra Trädgårdsgatan 15
111 53 Stockholm

<p>City image from a walkway, with a church and tall buildings in the background.</p>

R&D Offices

Emmy Noetherweg 2K
2333 BK Leiden
The Netherlands

<p>Overview image of a city, shot in low sunlight from a far distance.</p>

Gothenburg Office

Mendus C/O AstraZeneca BioventureHub
Pepparedsleden 1
431 83 Mölndal